Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sarepta to use GenEdit’s polymer nanoparticles to deliver gene editors

by Michael McCoy
February 4, 2022 | A version of this story appeared in Volume 100, Issue 5

Gene-editing pioneer Sarepta Therapeutics will use GenEdit’s polymer nanoparticle delivery system to develop gene-editing therapies for neuromuscular diseases. GenEdit raised $26 million in series A funding in September to advance its system as an alternative to lipid nanoparticles and viral vectors for delivering RNA and DNA. Sarepta’s three approved products, all treatments for Duchenne muscular dystrophy, are delivered with viral vectors. GenEdit could get up to $57 million in near-term payments.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.